vimseltinib   Click here for help

GtoPdb Ligand ID: 11190

Synonyms: compound 20 [PMID: 35961460] | DCC-3014 | DCC3014 | example 10 [WO2014145025A2]
PDB Ligand
Compound class: Synthetic organic
Comment: The chemical structure submitted to the WHO for the INN vimseltinib is identical to that of the investigational, oral CSF1R inhibitor DCC-3014, via a PubChem structure match. The compound is claimed as example 10 in Deciphera Pharmaceuticals' patent WO2014145025A2, in which KIT proto-oncogene inhibitory activity is also noted [1]. Name to structure was formally disclosed in Caldwell et al. (2022) [2]. Vimseltinib's selectivity is determined by its interactions within the switch control region of the CSF1R that regulates kinase conformational activation.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 99.75
Molecular weight 431.21
XLogP 3.58
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC(Nc1ncc(c(=O)n1C)c1ccc(c(n1)C)Oc1ccnc(c1)c1cnn(c1)C)C
Isomeric SMILES CC(Nc1ncc(c(=O)n1C)c1ccc(c(n1)C)Oc1ccnc(c1)c1cnn(c1)C)C
InChI InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
1. Ahn Y,Vogeti L, Caldwell TM, Kaufman MD, Flynn DL. (2014)
2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities.
Patent number: WO2014145025A2. Assignee: Deciphera Pharmaceuticals, Llc. Priority date: 15/03/2013. Publication date: 18/09/2014.
2. Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, Vogeti L, Vogeti S, Kaufman MD, Wise SC et al.. (2022)
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Bioorg Med Chem Lett, 74: 128928. [PMID:35961460]
3. Smith BD, Kaufman MD, Wise SC, Ahn YM, Caldwell TM, Leary CB, Lu WP, Tan G, Vogeti L, Vogeti S et al.. (2021)
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Mol Cancer Ther, 20 (11): 2098-2109. [PMID:34433663]